Biogen said global TYSABRI revenue decreased from $431.3 million to $381.5 million, or 11.5%, and TECFIDERA revenue decreased from $254.3 million to $206.1 million, or 19.0%, for Q1 2025.

1. 01

   Biogen said global TYSABRI revenue decreased from $431.3 million to $381.5 million, or 11.5%, and TECFIDERA revenue decreased from $254.3 million to $206.1 million, or 19.0%, for Q1 2025.

2. 02

   The company said global SKYCLARYS revenue increased from $78.0 million to $123.9 million, or 58.8%, and rest of world SPINRAZA revenue increased from $192.8 million to $269.5 million, or 39.8%, for Q1 2025.

3. 03

   Biogen cited an $165.0 million upfront payment to Stoke upon closing of the collaboration and license agreement in February 2025 and an $35.0 million milestone payment to MorphoSys accrued during Q1 2025 as factors in the increase in acquired in-process research and development, upfront and milestone expense.

4. 04

   The company said it entered into a lease agreement for approximately 580,000 square feet of space at 75 Broadway, Cambridge, Massachusetts in March 2025. The initial lease term is approximately 15.5 years, with estimated minimum lease payments of approximately $1.5 billion.

Key figures

Quarter ended March 31, 2025

Revenue

$2.4B

Net income

$241M

EPS

$1.64

Operating cash flow

$259M

Analysis scope · Management's discussion (MD&A)We analyzed excerpts of the Management's Discussion and Analysis (MD&A) section (with omissions). Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.